Convergentrx
1 known investors
Convergent Therapeutics develops radioantibody (targeted alpha-particle radiopharmaceutical) therapies for cancer patients, including its lead candidate CONV01-α for metastatic castration-resistant prostate cancer. The company operates in the oncology and radiopharmaceutical drug development space.
BiotechHealthtech
Investors · 1
Frequently asked questions
- What does Convergentrx do?
- Convergent Therapeutics develops radioantibody (targeted alpha-particle radiopharmaceutical) therapies for cancer patients, including its lead candidate CONV01-α for metastatic castration-resistant prostate cancer. The company operates in the oncology and radiopharmaceutical drug development space.
- Who are Convergentrx's investors?
- Convergentrx's investors include OrbiMed.